Seer(US:SEER)2025-11-06 21:30Financial Performance - Q3 2025 revenue reached $4.1 million[6,21] - The company holds approximately $251 million in cash, cash equivalents, and investments[6,21] - Gross margin for Q3 2025 was 51%, compared to 48% in Q3 2024[21] - Net loss for Q3 2025 was $18.2 million, an improvement from the $21.3 million net loss in Q3 2024[21] - The company repurchased approximately 1 million shares in Q3, bringing the total to approximately 11.7 million shares, reducing net total shares outstanding by approximately 14%[22] - The company reiterates full year 2025 revenue guidance of $17 million to $18 million, representing 24% year-over-year growth at the midpoint[23] Product and Platform Adoption - The company delivered the third consecutive quarter of strong instrument shipments[7] - The Proteograph ONE workflow doubles throughput to 80 samples per run, with an approximate 30% reduction in run time to approximately 4.5 hours compared to Proteograph XT[11] - The Proteograph ONE workflow can analyze over 1,000 samples per week[11] - The company shipped nearly three times as many instruments in the first nine months of 2025 as in all of 2024[20]